Melanocortin MC₄ receptor agonists counteract late inflammatory and apoptotic responses and improve neuronal functionality after cerebral ischemia.

[1]  S. Guarini,et al.  Early treatment with ACTH-(1-24) in a rat model of hemorrhagic shock prolongs survival and extends the time-limit for blood reinfusion to be effective. , 1990, Critical care medicine.

[2]  W. Banks,et al.  Permeability of the blood-brain barrier to melanocortins , 1995, Peptides.

[3]  V. Sogos,et al.  Effect of dystrophin antisense oligonucleotides on cultured human neurons , 1997, Neurochemistry International.

[4]  A. Beckmann,et al.  Egr transcription factors in the nervous system , 1997, Neurochemistry International.

[5]  J. Wikberg,et al.  Discovery of a novel superpotent and selective melanocortin-4 receptor antagonist (HS024): evaluation in vitro and in vivo. , 1998, Endocrinology.

[6]  F R Sharp,et al.  Increased Neurogenesis in the Dentate Gyrus After Transient Global Ischemia in Gerbils , 1998, The Journal of Neuroscience.

[7]  R. Seeley,et al.  A Novel Selective Melanocortin-4 Receptor Agonist Reduces Food Intake in Rats and Mice without Producing Aversive Consequences , 2000, The Journal of Neuroscience.

[8]  K. Nozaki,et al.  Activation of Mitogen-Activated Protein Kinases after Transient Forebrain Ischemia in Gerbil Hippocampus , 2000, The Journal of Neuroscience.

[9]  D. Zaffe,et al.  Protective effect of melanocortin peptides in rat myocardial ischemia. , 2001, The Journal of pharmacology and experimental therapeutics.

[10]  S. Guarini,et al.  Survival rate after early treatment for acute type-A aortic dissection with ACTH-(1–24) , 2001, The Lancet.

[11]  Paolo Grieco,et al.  Structure-activity studies of the melanocortin peptides: discovery of potent and selective affinity antagonists for the hMC3 and hMC4 receptors. , 2002, Journal of medicinal chemistry.

[12]  David J Gladstone,et al.  Toward Wisdom From Failure: Lessons From Neuroprotective Stroke Trials and New Therapeutic Directions , 2002, Stroke.

[13]  J. B. Tatro,et al.  α-melanocyte stimulating hormone suppresses intracerebral tumor necrosis factor-α and interleukin-1β gene expression following transient cerebral ischemia in mice , 2002, Neuroscience Letters.

[14]  E. Shohami,et al.  Cerebral ischemia and trauma—different etiologies yet similar mechanisms: neuroprotective opportunities , 2002, Brain Research Reviews.

[15]  Kevin J. Tracey,et al.  The inflammatory reflex , 2002, Nature.

[16]  Á. Chamorro,et al.  Levels of Anti-Inflammatory Cytokines and Neurological Worsening in Acute Ischemic Stroke , 2003, Stroke.

[17]  Robert M Friedlander,et al.  Apoptosis and caspases in neurodegenerative diseases. , 2003, The New England journal of medicine.

[18]  J. M. Lipton,et al.  α-melanocyte-stimulating hormone is decreased in plasma of patients with acute brain injury , 2003 .

[19]  P. Grieco,et al.  Extensive structure-activity studies of lactam derivatives of MT-II and SHU-9119: their activity and selectivity at human melanocortin receptors 3, 4, and 5. , 2003, The journal of peptide research : official journal of the American Peptide Society.

[20]  L. Minutoli,et al.  Efferent Vagal Fibre Stimulation Blunts Nuclear Factor-&kgr;B Activation and Protects Against Hypovolemic Hemorrhagic Shock , 2003, Circulation.

[21]  J. M. Lipton,et al.  Targeting Melanocortin Receptors as a Novel Strategy to Control Inflammation , 2004, Pharmacological Reviews.

[22]  D. Altavilla,et al.  Adrenocorticotropin reverses hemorrhagic shock in anesthetized rats through the rapid activation of a vagal anti-inflammatory pathway. , 2004, Cardiovascular research.

[23]  A. Bitto,et al.  Activation of an efferent cholinergic pathway produces strong protection against myocardial ischemia/reperfusion injury in rats* , 2005, Critical care medicine.

[24]  A. Bitto,et al.  Broad therapeutic treatment window of [Nle(4), D-Phe(7)]alpha-melanocyte-stimulating hormone for long-lasting protection against ischemic stroke, in Mongolian gerbils. , 2006, European journal of pharmacology.

[25]  J. B. Tatro.  Melanocortins defend their territory: multifaceted neuroprotection in cerebral ischemia. , 2006, Endocrinology.

[26]  E. Ringelstein,et al.  Toward a Multimodal Neuroprotective Treatment of Stroke , 2006, Stroke.

[27]  A. Bitto,et al.  Both early and delayed treatment with melanocortin 4 receptor-stimulating melanocortins produces neuroprotection in cerebral ischemia. , 2006, Endocrinology.

[28]  Geoffrey A. Donnan,et al.  Experimental Treatments in Acute Stroke , 2006 .

[29]  Adnan I. Qureshi,et al.  Guidelines for the Early Management of Adults With Ischemic Stroke , 2007 .

[30]  A. Bitto,et al.  Neuroprotection in focal cerebral ischemia owing to delayed treatment with melanocortins. , 2007, European journal of pharmacology.

[31]  F. Gage,et al.  Experience-Specific Functional Modification of the Dentate Gyrus through Adult Neurogenesis: A Critical Period during an Immature Stage , 2007, The Journal of Neuroscience.

[32]  M. Galantucci,et al.  Selective melanocortin MC4 receptor agonists reverse haemorrhagic shock and prevent multiple organ damage , 2007, British journal of pharmacology.

[33]  K. Tracey.  Physiology and immunology of the cholinergic antiinflammatory pathway. , 2007, The Journal of clinical investigation.

[34]  E. Novellino,et al.  Further structure–activity studies of lactam derivatives of MT-II and SHU-9119: Their activity and selectivity at human melanocortin receptors 3, 4, and 5 , 2007, Peptides.

[35]  A. Catania.  Neuroprotective actions of melanocortins: a therapeutic opportunity , 2008, Trends in Neurosciences.

[36]  R. Nargund,et al.  Lack of Protection with a Novel, Selective Melanocortin Receptor Subtype-4 Agonist RY767 in a Rat Transient Middle Cerebral Artery Occlusion Stroke Model , 2008, Pharmacology.

[37]  J. Wikberg,et al.  Targeting melanocortin receptors: an approach to treat weight disorders and sexual dysfunction , 2008, Nature Reviews Drug Discovery.

[38]  A. Bitto,et al.  Vagus Nerve Mediates the Protective Effects of Melanocortins against Cerebral and Systemic Damage after Ischemic Stroke , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[39]  G. Cuny.  Kinase inhibitors as potential therapeutics for acute and chronic neurodegenerative conditions. , 2009, Current pharmaceutical design.

[40]  A. Coll,et al.  Science of self-preservation: how melanocortin action in the brain modulates body weight, blood pressure, and ischemic damage. , 2009, Circulation.

[41]  A. Bitto,et al.  Functional recovery after delayed treatment of ischemic stroke with melanocortins is associated with overexpression of the activity-dependent gene Zif268 , 2009, Brain, Behavior, and Immunity.

[42]  C. Ali,et al.  Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic , 2009, Trends in Neurosciences.

[43]  K. Unsicker,et al.  ERK and cell death: ERK1/2 in neuronal death , 2010, The FEBS journal.

[44]  Luca Spaccapelo,et al.  Melanocortins counteract inflammatory and apoptotic responses to prolonged myocardial ischemia/reperfusion through a vagus nerve-mediated mechanism. , 2010, European journal of pharmacology.

[45]  Eng H. Lo,et al.  The Science of Stroke: Mechanisms in Search of Treatments , 2010, Neuron.

[46]  J. Thayer,et al.  Neural aspects of immunomodulation: Focus on the vagus nerve , 2010, Brain, Behavior, and Immunity.

[47]  G. Leoni,et al.  Melanocortin control of cell trafficking in vascular inflammation. , 2010, Advances in experimental medicine and biology.

[48]  A. Ottani,et al.  Melanocortins and the cholinergic anti-inflammatory pathway. , 2010, Advances in experimental medicine and biology.

[49]  C. Hobohm,et al.  A novel quantification of blood–brain barrier damage and histochemical typing after embolic stroke in rats , 2010, Brain Research.

[50]  K. Baldwin,et al.  Acute Ischemic Stroke Update , 2010, Pharmacotherapy.

[51]  Sung-Chun Tang,et al.  Pathophysiology, treatment, and animal and cellular models of human ischemic stroke , 2011, Molecular Neurodegeneration.

[52]  K. Mountjoy.  Distribution and function of melanocortin receptors within the brain. , 2010, Advances in experimental medicine and biology.

[53]  R. Flower,et al.  Targeting the melanocortin receptor system for anti-stroke therapy. , 2011, Trends in pharmacological sciences.

[54]  Kathryn J. Jones,et al.  IL-10 within the CNS is necessary for CD4+ T cells to mediate neuroprotection , 2011, Brain, Behavior, and Immunity.

[55]  Luca Spaccapelo,et al.  Melanocortins protect against multiple organ dysfunction syndrome in mice , 2011, British journal of pharmacology.